Brief: Actinium Announces Initiation Of Patient Enrollment In Iomab-ACT Trial
24/03/2021 11:36
March 24 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM ANNOUNCES INITIATION OF PATIENT ENROLLMENT IN
IOMAB-ACT
TRIAL FOR TARGETED CONDITIONING PRIOR TO CD19 CAR T-CELL THERAPY
* ACTINIUM PHARMACEUTICALS INC - CLINICAL PROOF-OF-CONCEPT
DATA
EXPECTED IN 2H:2021 FROM FIRST OF ITS KIND TRIAL FUNDED BY NIH
STTR GRANT
Source text for Eikon: ID:nPn559Fqqa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities